Anti-Inflammatory Mechanisms of Apolipoprotein A-I Mimetic Peptide in Acute Respiratory Distress Syndrome Secondary to Sepsis
Open Access
- 14 May 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5), e64486
- https://doi.org/10.1371/journal.pone.0064486
Abstract
Acute respiratory distress syndrome (ARDS) due to sepsis has a high mortality rate with limited treatment options. High density lipoprotein (HDL) exerts innate protective effects in systemic inflammation. However, its role in ARDS has not been well studied. Peptides such as L-4F mimic the secondary structural features and functions of apolipoprotein (apo)A-I, the major protein component of HDL. We set out to measure changes in HDL in sepsis-mediated ARDS patients, and to study the potential of L-4F to prevent sepsis-mediated ARDS in a rodent model of lipopolysaccharide (LPS)-mediated acute lung injury, and a combination of primary human leukocytes and human ARDS serum. We also analyzed serum from non-lung disease intubated patients (controls) and sepsis-mediated ARDS patients. Compared to controls, ARDS demonstrates increased serum endotoxin and IL-6 levels, and decreased HDL, apoA-I and activity of anti-oxidant HDL-associated paraoxanase-1. L-4F inhibits the activation of isolated human leukocytes and neutrophils by ARDS serum and LPS in vitro. Further, L-4F decreased endotoxin activity and preserved anti-oxidant properties of HDL both in vitro and in vivo. In a rat model of severe endotoxemia, L-4F significantly decreased mortality and reduces lung and liver injury, even when administered 1 hour post LPS. Our study suggests the protective role of the apoA-I mimetic peptide L-4F in ARDS and gram-negative endotoxemia and warrant further clinical evaluation. The main protective mechanisms of L-4F are due to direct inhibition of endotoxin activity and preservation of HDL anti-oxidant activity.Keywords
This publication has 59 references indexed in Scilit:
- D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthmaJournal of Lipid Research, 2011
- Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-functionJournal of Lipid Research, 2011
- Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL functionJournal of Lipid Research, 2011
- A Self-Propagating Matrix Metalloprotease-9 (MMP-9) Dependent Cycle of Chronic Neutrophilic InflammationPLOS ONE, 2011
- The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic ratsJournal of Lipid Research, 2010
- Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophagesAmerican Journal of Physiology-Cell Physiology, 2010
- Modification of High Density Lipoprotein by Myeloperoxidase Generates a Pro-inflammatory ParticleJournal of Biological Chemistry, 2009
- Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-IJournal of Lipid Research, 2008
- Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patientsJournal of Lipid Research, 2008